Evotec SE (0IRF.L)

25,91 +0,48 (+1,88%) Al 06:18PM BST. Mercato aperto.

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 4.715

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.	Chairman of Management Board & CEO	1,3M	N/D	1968
Mr. Enno Spillner	CFO & Member of Management Board	604k	N/D	1970
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	726k	N/D	1964
Dr. Craig Johnstone	COO & Member of Management Board	616k	N/D	1970
Dr. Matthias Evers	Chief Bus. Officer & Member of Management Board	N/D	N/D	1973
Ms. Anja Bosler	Principal Accounting Officer and Sr. VP of Group Accounting	N/D	N/D	N/D
Mr. Volker Braun	Sr. VP and Global Head of Investor Relations & ESG	N/D	N/D	N/D
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/D	N/D	N/D
Gabriele Hansen	Sr. VP & Head of Global Corp. Communications & Marketing	N/D	N/D	N/D
Ms. Monika Conradt	Global Head of HR	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Evotec SE al 1 marzo 2023 è 7. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.